Where GFAP is reported
Also listed as: Glial fibrillary acidic protein
| Condition | Direction | Compared against | Associated symptoms | Source |
|---|---|---|---|---|
| Long COVID | ↑ elevated | healthy controls | Neurological LC, astrocyte activation | Lai et al. 2023 |
| Multiple Sclerosis | ↑ elevated | progressive MS vs healthy/non-progressive | — | Chitnis et al. 2025 |
Frequently asked questions
In which conditions is GFAP altered?
In the OSMF atlas GFAP is reported in Long COVID, Multiple Sclerosis. It is elevated in 2 across 2 entries.
Does GFAP point to one specific diagnosis?
No. Because GFAP changes in several conditions (Long COVID, Multiple Sclerosis), an abnormal result cannot identify which condition, if any, is present. It must be interpreted with symptoms, history and other tests.
Is there a standard clinical test for GFAP?
The atlas entries for GFAP do not carry a LOINC code, which usually means the marker was measured with research assays or study-specific methods rather than a routine clinical panel.
Is one abnormal GFAP result diagnostic?
No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.
Cite this page
Subscribe on Substack
Last reviewed: 2026-07-03 · Browse: Biomarker Index · All marker pages · Biomarker Atlas
Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.